Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer

Table 2 Patient characteristics at recurrence diagnosis and recurrence treatment

Parameters	No. of patients	Proportion of patients (%)
Age at recurrence diagnosis
Median(y)	49	–
Range(y)	34–69	–
≤50 y	30	58.8
>50y	21	41.2
Disease-free interval
<1 year	16	31.4
1–2 year	11	21.6
>2 year	24	47.1
Site of recurrence (n = 61^a)
Chest wall (CW)	20	32.8
Supraclavicular nodes (SC)	19	31.1
Internal mammary lymph nodes (IM)	11	18.0
Axillary lymph nodes (Ax)	11	18.0
No. of recurrence
Single nodule	25	49.0
Multiple nodules	20	39.2
Diffuse growth	6	11.8
Size of largest recurrence
<3 cm	32	62.7
≥3 cm	19	37.3
Radiotherapy fields (CTV1) ^c
CW + SC&IC only	18	35.3
CW + SC&IC + neck	11	21.6
CW + SC&IC + Ax	6	11.8
CW + SC&IC + IM	8	15.7
CW + SC&IC + neck + IM	3	5.9
CW + SC&IC + neck + Ax	5	9.8
Systemic treatment after concurrent CRT^b
None	9	17.6
Chemotherapy	8	15.7
Hormone therapy	30	58.8
Sequential chemotherapy and hormone therapy	2	3.9
HER2-targeted therapy and hormone therapy	2	3.9

^a: Multiple locoregional recurrences represented 10 patients (3 patients with supraclavicular node and intramammary lymph node; 5 with supraclavicular and axillary lymph node; 1 with supraclavicular node and chest wall; 1 with chest wall and axillary lymph node)
^bConcurrent CRT: Concurrent radiation therapy and paclitaxel
^cCW chest wall, SC&IC supra- and infraclavicular regions, Ax axillary lymph node, IM intramammary lymph node

ISSN: 1748-717X